<img src="https://ws.zoominfo.com/pixel/eCRg8hzy2qp0kNUl6E1g" width="1" height="1" style="display: none;">

Press Releases

Jump to a page: News Media Kit

Independent Data Demonstrates Clinical Utility of Biodesix®’ Blood-Based Tests

Data from an independent study demonstrated the clinical utiity of Biodesix' VeriStrat and GeneStrat tests.

Independent Study Data Supporting Clinical Use of Biodesix®’ Blood-Based Tests To Be Presented At CHEST Conference

Independent Study Data supports clinical use of Biodesix’s blood-based tests at CHEST conference.

VeriStrat® Test Identifies Patients with Squamous Cell Carcinoma of the Lung Who Are More Likely to Have Improved Survival on Afatinib Therapy

VeriStrat® Test identifies patients with squamous cell carcinoma of the lung who are more likely to have improved survival on Afatinib therapy.

Biodesix®’ VeriStrat® Test Identifies T790M-Mutated Advanced Non-Small Cell Lung Cancer Patients Who Are More Likely to Have Improved Progression-Free Survival on Third Generation EGFR-TKI Therapy

Biodesix's VeriStrat test identifies T790M-mutated advanced non-small cell lung cancer patients who are more likely to have improved progression-free survival on third generation EGFR-TKI therapy

Multi-Institutional Data Supporting Clinical Use of Biodesix’ Blood-Based Tests Presented Today at IASLC Conference

Multi-institutional data supporting clinical use of Biodesix blood tests was presented at the IASCL Chicago thoracic conference

Biodesix’ Nicholas Dupuis, Ph. D, Speaking at MSACL 3rd Annual Conference

Biodesix’ Nicholas Dupuis, Ph. D, Speaking at MSACL 3rd Annual Conference

Wellmark BCBS of Iowa and South Dakota Provides Coverage for VeriStrat® Test

Biodesix press release: Wellmark BCBS of Iowa and South Dakota provides coverage for VeriStrat® Test

Heinrich Roder to speak at 6th International Conference on Bioinformatics & Systems Biology

Heinrich Roder will speak at the 6th International Conference on Bioinformatics and Systems Biology

Biodesix Raises Follow-On Series F Financing

Biodesix raises an additional $7 million in series F financing.

Horizon Blue Cross Blue Shield of New Jersey Provides Coverage for Biodesix’ VeriStrat Test

Horizon Blue Cross Blue Shield (BCBS) of New Jersey has determined that the VeriStrat® proteomic test is now considered a medically necessary benefit for members with advanced NSCLC.